BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) - Research analysts at HC Wainwright cut their Q4 2025 EPS estimates for shares of BioHarvest Sciences in a note issued to investors on Monday, May 19th. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings of $0.00 per share for the quarter, down from their previous forecast of $0.01. HC Wainwright currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for BioHarvest Sciences' current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences' FY2026 earnings at $0.07 EPS, FY2027 earnings at $0.34 EPS, FY2028 earnings at $0.72 EPS and FY2029 earnings at $1.19 EPS.
Separately, Craig Hallum began coverage on BioHarvest Sciences in a research note on Monday, May 5th. They set a "buy" rating and a $15.00 target price for the company.
Check Out Our Latest Stock Analysis on BioHarvest Sciences
BioHarvest Sciences Stock Performance
Shares of BioHarvest Sciences stock traded up $0.14 during trading hours on Tuesday, hitting $6.29. 10,027 shares of the company's stock traded hands, compared to its average volume of 17,352. The stock has a 50 day moving average of $6.16. The stock has a market cap of $103.31 million, a P/E ratio of -5.04 and a beta of 0.80. BioHarvest Sciences has a twelve month low of $6.12 and a twelve month high of $7.38.
BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. The company had revenue of $7.64 million during the quarter, compared to analyst estimates of $8.93 million.
Hedge Funds Weigh In On BioHarvest Sciences
Hedge funds have recently bought and sold shares of the company. TD Waterhouse Canada Inc. acquired a new position in BioHarvest Sciences in the fourth quarter worth about $69,000. True North Advisors LLC grew its stake in BioHarvest Sciences by 7.6% in the first quarter. True North Advisors LLC now owns 44,391 shares of the company's stock worth $275,000 after purchasing an additional 3,120 shares in the last quarter. Finally, Magnus Financial Group LLC grew its stake in BioHarvest Sciences by 105.0% in the first quarter. Magnus Financial Group LLC now owns 71,733 shares of the company's stock worth $444,000 after purchasing an additional 36,733 shares in the last quarter.
BioHarvest Sciences Company Profile
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
Read More
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
